Par Health, Inc.New on the radar☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Par Health, Inc. is one of 1613 Pharmaceuticals companies tracked from St. Louis. By capital raised it ranks among the largest (ahead of 100% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Learn how Par Health’s legacy, values, and people shape a culture of excellence, integrity and unwavering dedication to those we serve.

Learn how Par Health’s legacy, values, and people shape a culture of excellence, integrity and unwavering dedication to those we serve. We’re Par Health, the essential pharmaceutical company. Par Health was born from the merger of Mallinckrodt and Endo—two legacy companies with over a century of experience in essential medicines. Both began as family-run businesses, united by a commitment to integrity and innovation. Our manufacturing footprint includes the historic API site in St. Louis, Missouri—founded over 160 years ago by three brothers with a bold vision. It remains central to our operations today. We also carry forward the legacy of our Rochester, Michigan facility, which earned the first FDA Biologics license for polio vaccine manufacturing. These sites are joined by eight additional facilities across the US and India, forming a global manufacturing and supply network that delivers high-quality medicines with consistency and scale. This history isn’t just behind us—it fuels our purpose today. It’s why we manufacture every product with precision and intention. So, when patients need treatment, providers can trust our medicines to meet their needs and support better outcomes.

Trades publicly as About Our Company.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Growth/Late — a round over $400M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 100% of sector peers (real $). Modeled value above 99% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Growth/Late) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.

Not enough valued peers in this cohort to chart positioning.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Growth/Late$763.0M2025-11-10
   • First recorded raise — entered as Growth/Late.
   • 234 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Par Health, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Par Health, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Par Health, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.